Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Identification of hsa-miR-144-3p as a novel immunotherapeutic target for glioblastoma based on disulfidptosis-related analysis.
Journal: Discover oncology
Published: September 25, 2025
Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma.
Journal: Cancers
Published: April 18, 2025
A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an EGFR tyrosine kinase inhibitor-treated non-small-cell lung cancer patient.
Journal: Biomarkers in medicine
Published: July 15, 2024
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Journal: JCO precision oncology
Published: July 10, 2024
Pembrolizumab in an HIV-infected patient with glioblastoma.
Journal: Immunotherapy
Published: June 18, 2024
Metastatic glioblastoma to the lungs: a case report and literature review.
Journal: CNS oncology
Published: June 12, 2024
Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study.
Journal: Journal of the advanced practitioner in oncology
Published: February 02, 2023
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 29, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide.
Journal: Frontiers in oncology
Published: May 02, 2022
Last Updated: 09/26/2026